Clinical trial
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
NCT00005594 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00005594 |
|---|---|
| Title | ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas |
| Official title | Phase II Trial of ISIS 2503, an Antisense Inhibitor of H-Ras, in Patients With Advanced Pancreatic Cancer |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH Ionis Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | ISIS 2503 |
| Enrollment | 4 |
| Start date | Jul 1, 2000 |
| Primary completion | Dec 1, 2000 |
| First posted | May 3, 2004 |
| Last update posted | Jan 4, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: